Drugs / ALBUSOMATROPIN
ALBUSOMATROPIN
also known as
TV-1106 · Albusomatropina · Albusomatropine · Albutropin · Somatropin-albumin fusion protein
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 22 trials | ||||||
| Phase 2 | NCT02092077 | Apr 2014 → Apr 2016 | pituitary deficiency | Teva Pharmaceutical Industries, Ltd. | Terminated | No outcome recorded |
| Phase 2 | NCT01811576 | Mar → Aug 2013 | pituitary deficiency | Teva Branded Pharmaceutical Products R&D, Inc. | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT02410343 | Apr → Dec 2015 | pituitary deficiency | Teva Branded Pharmaceutical Products R&D, Inc. | Terminated | No outcome recorded |
| Phase 3 | NCT02410356 | Apr 2015 → Feb 2016 | pituitary deficiency | Teva Branded Pharmaceutical Products R&D, Inc. | Terminated | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ALBUSOMATROPIN | ChEMBL registry synonym — accepted as the source's own label CHEMBL4298125 ↗ |
| Known as | Albusomatropina | ChEMBL registry synonym — accepted as the source's own label CHEMBL4298125 ↗ |
| Known as | Albusomatropine | ChEMBL registry synonym — accepted as the source's own label CHEMBL4298125 ↗ |
| Known as | Albutropin | ChEMBL registry synonym — accepted as the source's own label CHEMBL4298125 ↗ |
| Known as | Somatropin-albumin fusion protein | ChEMBL registry synonym — accepted as the source's own label CHEMBL4298125 ↗ |
| Known as | TV-1106 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02410343 ↗ |
| Modality | Protein / enzyme biologic | “long-acting growth hormone” NCT02410343 ↗ |
| Route | Subcutaneous | “TV-1106 was injected subcutaneously once weekly” NCT02410343 ↗ |